| A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication 1999 · policosanol · Patients with intermittent claudication; age and sex not specified | 20 mg | 26 weeks | 31 |
| A long-term study of policosanol in the treatment of intermittent claudication 2001 · policosanol · Patients with moderately severe intermittent claudication | 20 mg | 2 years | — |
| Effects of policosanol and lovastatin in patients with intermittent claudication: a double-blind comparative pilot study 2003 · policosanol · Patients with moderately severe intermittent claudication; age and sex not specified | 10 mg | 20 weeks | — |
| Effects of policosanol and ticlopidine in patients with intermittent claudication: a double-blinded pilot comparative study 2004 · policosanol · Adults with moderately severe intermittent claudication | 20 mg | 20 weeks | — |
| Effects of policosanol (10 mg/d) versus aspirin (100 mg/d) in patients with intermittent claudication: a 10-week, randomized, comparative study 2008 · policosanol · Patients with intermittent claudication | 10 mg | 10 weeks | — |
| Effects of policosanol in the functional recovery of non-cardioembolic ischemic stroke hypertensive patients 2018 · policosanol + aspirin · Hypertensive patients, mean age 66 years, with recent non-cardioembolic ischemic stroke and modified Rankin Scale score 2 to 4 | 20 mg | 26 weeks | — |
| Efficacy and Safety of Policosanol (Sugarcane Wax Alcohols) 20 mg/Day in Cuban Prehypertensive Patients: A Randomized, Double-Blind, Multicentre Study 2025 · Policosanol · Women and men aged 20–60 with prehypertension and 0–2 cardiovascular risk factors | 20 mg | 12 weeks | 100 |
| Policosanol (sugarcane wax alcohols) 20 mg/day in Cuban Patients With Grade I Hypertension: A Randomized, Double-Blind, Multicenter Study 2025 · Policosanol · Women and men aged 20–60 years with grade I hypertension and 0–2 cardiovascular risk factors | 20 mg | 12 weeks | 100 |
| [Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia] 1999 · policosanol · Patients with type II hypercholesterolemia and LDL cholesterol over 160 mg/dl | 10 mg | 8 weeks | 55 |
| Comparison of the efficacy, safety and tolerability of original policosanol versus other mixtures of higher aliphatic primary alcohols in patients with type II hypercholesterolemia 2002 · policosanol group, 10 mg/day step · Patients with type II hypercholesterolemia; age and sex not specified | 10 mg | 5 weeks | 55 |
| Beneficial Effect of Cuban Policosanol on Blood Pressure and Serum Lipoproteins Accompanied with Lowered Glycated Hemoglobin and Enhanced High-Density Lipoprotein Functionalities in a Randomized, Placebo-Controlled, and Double-Blinded Trial with Healthy Japanese 2023 · policosanol group · Healthy Japanese men and women aged 20–65 years with normal blood pressure and LDL-C of 120–<160 mg/dL | 20 mg | 12 weeks | 36 |
| Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study 2001 · policosanol 20 mg/day · Patients with type II hypercholesterolemia | 20 mg | 24 weeks | 29 |
| A comparison of the effects of D-003 and policosanol (5 and 10 mg/day) in patients with type II hypercholesterolemia: a randomized, double-blinded study 2005 · Policosanol 10 mg/day · Patients with type II hypercholesterolemia; age and sex not reported | 10 mg | 8 weeks | 25 |
| Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus 2002 · policosanol · Adults with dyslipidemia associated with type 2 diabetes mellitus | 10 mg | 8 weeks | 18 |
| Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors 1999 · Policosanol group, next 12 weeks · Patients with type II hypercholesterolemia and additional coronary risk factors | 10 mg | 12 weeks | — |
| Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients 1999 · policosanol · Older patients with type II hypercholesterolemia, LDL cholesterol above 3.4 mmol/l, and high coronary risk | 10 mg | 8 weeks | — |
| Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus 1999 · policosanol · Patients with hypercholesterolemia and noninsulin dependent diabetes mellitus | 10 mg | 12 weeks | — |
| Consumption of Cuban Policosanol Improves Blood Pressure and Lipid Profile via Enhancement of HDL Functionality in Healthy Women Subjects: Randomized, Double-Blinded, and Placebo-Controlled Study 2018 · policosanol group · Women aged 18–65 with prehypertension and no known endocrinological disorder | 10 mg | 8 weeks | — |
| Efficacy and Safety of Policosanol Plus Fenofibrate Combination Therapy in Elderly Patients with Mixed Dyslipidemia: A Randomized, Controlled Clinical Study 2018 · policosanol · Patients aged 60 years or older with mixed dyslipidemia | 20 mg | 24 weeks | — |
| Efficacy and Safety of Policosanol Plus Fenofibrate Combination Therapy in Elderly Patients with Mixed Dyslipidemia: A Randomized, Controlled Clinical Study 2018 · fenofibrate + policosanol combination · Patients aged 60 years or older with mixed dyslipidemia | 20 mg | 24 weeks | — |
| Short-Term Consumption of Cuban Policosanol Lowers Aortic and Peripheral Blood Pressure and Ameliorates Serum Lipid Parameters in Healthy Korean Participants: Randomized, Double-Blinded, and Placebo-Controlled Study 2019 · policosanol 10 mg group · Men and women aged 19–65 with prehypertension and no history of endocrinological disorder | 10 mg | 12 weeks | — |
| Short-Term Consumption of Cuban Policosanol Lowers Aortic and Peripheral Blood Pressure and Ameliorates Serum Lipid Parameters in Healthy Korean Participants: Randomized, Double-Blinded, and Placebo-Controlled Study 2019 · policosanol 20 mg group · Men and women aged 19–65 with prehypertension and no history of endocrinological disorder | 20 mg | 12 weeks | — |
| Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment 1994 · policosanol, 5 mg twice daily (second 8 weeks) · Patients with type II primary hypercholesterolaemia and elevated serum LDL-C and total cholesterol after a diet-only period | 10 mg | 8 weeks | — |
| Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment 1994 · policosanol, 10 mg twice daily (third 8 weeks) · Patients with type II primary hypercholesterolaemia and elevated serum LDL-C and total cholesterol after a diet-only period | 20 mg | 8 weeks | — |
| Concomitant use of policosanol and beta-blockers in older patients 2004 · policosanol · Older hypercholesterolemic patients taking beta-blockers; age range and sex not specified | 5 mg | 3 years | 98 |
| Comparison of the efficacy, safety and tolerability of original policosanol versus other mixtures of higher aliphatic primary alcohols in patients with type II hypercholesterolemia 2002 · policosanol group, 5 mg/day step · Patients with type II hypercholesterolemia; age and sex not specified | 5 mg | 5 weeks | 55 |
| Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study 2001 · policosanol 40 mg/day · Patients with type II hypercholesterolemia | 40 mg | 24 weeks | 30 |
| A comparison of the effects of D-003 and policosanol (5 and 10 mg/day) in patients with type II hypercholesterolemia: a randomized, double-blinded study 2005 · Policosanol 5 mg/day · Patients with type II hypercholesterolemia; age and sex not reported | 5 mg | 8 weeks | 25 |
| Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors 1999 · Policosanol group, first 12 weeks · Patients with type II hypercholesterolemia and additional coronary risk factors | 5 mg | 12 weeks | — |
| Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment 1994 · policosanol, 5 mg once daily (first 8 weeks) · Patients with type II primary hypercholesterolaemia and elevated serum LDL-C and total cholesterol after a diet-only period | 5 mg | 8 weeks | — |
| Multiple functions of policosanol in elderly patients with dyslipidemia 2020 · Group B · Men and women aged 75 years or older with dyslipidemia | 10 mg | 52 weeks | 72 |
| Multiple functions of policosanol in elderly patients with dyslipidemia 2020 · Group A · Men and women aged 75 years or older with dyslipidemia | 20 mg | 52 weeks | 64 |
| Multiple functions of policosanol in elderly patients with dyslipidemia 2020 · Group D · Men and women aged 75 years or older with dyslipidemia | 10 mg | 52 weeks | 62 |
| [Effects of policosanol combined with simvastatin on serum lipids and sex hormones in male patients with hyperlipidemia] 2013 · treatment group · male patients with hyperlipidemia | 20 mg | 16 weeks | 60 |
| Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia 2003 · policosanol · Adults aged 60–80 with type II hypercholesterolaemia | 10 mg | 8 weeks | 38 |
| [Effects of policosanol on serum lipids and heme oxygenase-1 in patients with hyperlipidemia] 2012 · treatment group · Patients with hyperlipidemia; age and sex not stated | 20 mg | 16 weeks | 36 |
| Long-term therapy with policosanol improves treadmill exercise-ECG testing performance of coronary heart disease patients 1998 · policosanol · coronary heart disease patients with myocardial ischemia; age and sex not reported | 10 mg | 608 days | 15 |
| Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients 1998 · policosanol · Patients with type II hypercholesterolemia and total cholesterol >5.0 mmol/L despite dietary conditions, receiving step-one cholesterol-lowering therapy | 10 mg | 30 days | — |
| A comparative study of policosanol Versus acipimox in patients with type II hypercholesterolemia 1999 · policosanol · Patients with type II hypercholesterolemia | 10 mg | 8 weeks | — |
| Antiplatelet effects of policosanol (20 and 40 mg/day) in healthy volunteers and dyslipidaemic patients 2002 · policosanol 20 mg/day · healthy volunteers and patients with type II hypercholesterolaemia | 20 mg | 30 days | — |
| Treatment of hypercholesterolemia in NIDDM with policosanol 1995 · policosanol · Adults with non-insulin-dependent diabetes mellitus (NIDDM) and hypercholesterolemia | 10 mg | 12 weeks | — |
| A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia 1995 · Policosanol · Patients of both sexes with type II hyperlipoproteinaemia whose total cholesterol and LDL-C were insufficiently controlled by diet | 10 mg | 2 years | — |
| Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers 1996 · Policosanol 10 mg day-1 · Healthy volunteers | 10 mg | 7 days | — |
| Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers 1996 · Policosanol 20 mg day-1 · Healthy volunteers | 20 mg | 7 days | — |
| Comparative study of policosanol, aspirin and the combination therapy policosanol-aspirin on platelet aggregation in healthy volunteers 1997 · policosanol · healthy volunteers | 20 mg | 7 days | — |
| Comparative study of policosanol, aspirin and the combination therapy policosanol-aspirin on platelet aggregation in healthy volunteers 1997 · combination therapy policosanol-aspirin · healthy volunteers | 20 mg | 7 days | — |
| Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment 2012 · BBR/P/RR monotherapy · Adults with primary polygenic hypercholesterolemia who were statin-intolerant or declined statin treatment | 10 mg | 180 days | 152 |
| Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment 2012 · Supplementary BBR/P/RR in HeFH patients on stable statin treatment or statin plus ezetimibe · Adults with genotype-confirmed heterozygous familial hypercholesterolemia on stable-dose statins or statins plus ezetimibe | 10 mg | 90 days | 30 |
| Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment 2012 · Combined BBR/P/RR plus ezetimibe therapy · Adults with primary hypercholesterolemia selected for a low response to monotherapy | 10 mg | 90 days | 26 |
| Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia 2005 · omega-3 FA + policosanol 5 mg/day · Patients with type II hypercholesterolaemia | 5 mg | 8 weeks | — |
| Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia 2005 · omega-3 FA + policosanol 10 mg/day · Patients with type II hypercholesterolaemia | 10 mg | 8 weeks | — |
| A Randomized, Double-Blinded, Placebo-Controlled, Clinical Study of the Effects of a Nutraceutical Combination (LEVELIP DUO(®)) on LDL Cholesterol Levels and Lipid Pattern in Subjects with Sub-Optimal Blood Cholesterol Levels (NATCOL Study) 2020 · LEVELIP DUO® · Adults aged 30–75 with moderately hypercholesterolemic, sub-optimal blood cholesterol levels, without other cardiovascular risk factors and not taking lipid-lowering drugs | 10 mg | 8 weeks | 43 |
| Effects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endotelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trial 2015 · Combination A · Adults aged 18–70 with hypercholesterolemia not requiring statins or statin-intolerant | 10 mg | 4 weeks | 23 |
| Safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation: two-year follow-up results 2016 · group C · Patients with high on-treatment platelet reactivity after drug-eluting stent implantation; age and sex not reported | 40 mg | 26 weeks | 150 |
| Long-term therapy with policosanol improves treadmill exercise-ECG testing performance of coronary heart disease patients 1998 · policosanol plus aspirin · coronary heart disease patients with myocardial ischemia; age and sex not reported | 10 mg | 608 days | 15 |
| Antiplatelet effects of policosanol (20 and 40 mg/day) in healthy volunteers and dyslipidaemic patients 2002 · policosanol 40 mg/day · healthy volunteers and patients with type II hypercholesterolaemia | 40 mg | 30 days | — |
| Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers 1996 · Policosanol 40 mg day-1 · Healthy volunteers | 40 mg | 7 days | — |
| Efficacy of a nutraceutical combination on lipid metabolism in patients with metabolic syndrome: a multicenter, double blind, randomized, placebo controlled trial 2019 · Armolipid Plus (AP) · Adults aged 18–70 with metabolic syndrome and left ventricular hypertrophy; men and women | 10 mg | 24 weeks | 71 |
| Effect of policosanol on hyperlipidemia and coronary heart disease in middle-aged patients. A 14-month pilot study 1996 · policosanol group · Middle-aged outpatients with chronic coronary heart disease and primary or marginal hyperlipidemia | 2 mg | 426 days | 12 |
| The treatment of hypercholesterolemic children: efficacy and safety of a combination of red yeast rice extract and policosanols 2011 · Dietary supplement · Children aged 8–16 with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia | 10 mg | 8 weeks | 40 |
| Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study 2010 · nutraceutical combination (NC) · Adults with hypercholesterolemia; mean age 55 years; 26 males and 24 females were randomized across both arms | 10 mg | 10 weeks | 25 |
| Effects of poly-bioactive compounds on lipid profile and body weight in a moderately hypercholesterolemic population with low cardiovascular disease risk: a multicenter randomized trial 2014 · Intervention (Armolipid Plus/AP) · Men and women older than 18 years with mild-moderate hypercholesterolemia and elevated LDL-c, candidates for lifestyle intervention without hypolipemic drug treatment | 10 mg | 12 weeks | 51 |
| Effects of a New Combination of Medical Food on Endothelial Function and Lipid Profile in Dyslipidemic Subjects: A Pilot Randomized Trial 2019 · Nutraceutical B · Adults aged 18–75 with elevated serum cholesterol not requiring statins or statin-intolerant; people with cardiovascular disease and uncontrolled diabetes were excluded. | 10 mg | 6 weeks | 23 |